Novartis Sheds 13.2% After Lp(a) Cholesterol Trial Fails

Novartis shares fell 13.16% to 138.94 on Tuesday, September 8, 2026, after the company's trial of an Lp(a)-lowering cholesterol drug failed, dragging down other biopharma stocks pursuing the same cardiovascular target.

Novartis (NYSE: NVS) shares dropped 13.16% to 138.94 by 15:20 GMT on Tuesday, September 8, 2026, after the company disclosed that its trial of a cholesterol drug failed. The stock traded in a band of 138.28 to 140.46 through the session, well below the previous close of 159.99 — a range that suggests sellers set the price early and never let it recover.

The drug belongs to a class aimed at lipoprotein(a), usually written Lp(a): a cholesterol-carrying particle in the blood whose level is largely fixed by genetics rather than by diet or exercise. Elevated Lp(a) has long been associated with heart attacks and strokes, and Novartis — along with several other drugmakers — bet that pushing the number down would translate into fewer of those sometimes fatal cardiovascular events. That bet is what the trial was meant to prove, and it is what did not come through.

Why one company's readout repriced a whole field

The selloff spread beyond Novartis because the failure lands on the hypothesis, not just the molecule. When a trial misses because a single compound was poorly dosed or badly tolerated, rivals can argue their version is different. When it misses on the underlying premise — that moving a biomarker moves patient outcomes — every program pointed at that biomarker inherits the doubt.

Lp(a) has been an attractive target precisely because it is genetically determined and largely untouched by statins, the workhorse cholesterol drugs. That left a population of patients with a stubborn, measurable risk factor and no way to treat it, which is the textbook setup for a large commercial opportunity. Several drugmakers built programs around it. As MarketWatch reported, that shared wager is why the reaction was broad rather than contained.

The distinction that matters for the rest of the field is between biomarker effect and clinical effect. A drug can lower Lp(a) convincingly on a lab report and still fail to reduce the rate at which patients have heart attacks. Cardiovascular outcomes trials are long, large and expensive because that gap between the two is real and has caught the industry out before with other lipid targets.

What the tape says about the damage

The move in Novartis is severe by large-cap pharma standards. A drop of 13.16% in a single session is the kind of repricing normally reserved for a pipeline asset that was carrying material expected revenue, and it implies the market had assigned real value to the Lp(a) program rather than treating it as a lottery ticket.

The broader indices did not follow. The S&P 500 tracker (SPY) was at $768.12, down 0.27% from a prior close of $770.19, with a day range of $765.99 to $769.70. The Nasdaq 100 tracker (QQQ) was actually higher at $720.33, up 0.19%. The Dow tracker (DIA) was the weakest of the three at $528.95, down 0.96% from $534.08.

That pattern is worth reading carefully. A soft Dow alongside a firm Nasdaq 100 is consistent with damage concentrated in large, dividend-paying industrials and healthcare names rather than a market-wide risk-off move. In other words, the biopharma selloff was a sector event that leaked into the blue-chip average, not a macro event that happened to catch drugmakers.

The endpoint problem facing rival programs

Every company still running an Lp(a) outcomes trial now has to answer the same question from investors: what makes your trial different from the one that just failed? The credible answers are narrow. A different patient population — higher baseline Lp(a), more prior cardiovascular events — is one. A deeper or more durable reduction in the particle is another. A longer follow-up period, on the theory that the benefit takes years to separate from the control arm, is a third.

None of those arguments is free. Each implies either a smaller addressable patient group or a longer, costlier path to an answer, and both cut into the commercial case that made the target attractive in the first place. Boards that were weighing whether to fund the next phase of an Lp(a) asset will now be doing that arithmetic against a live example of what a miss costs the share price.

There is also a regulatory dimension. Approvals in cardiovascular medicine have generally required hard outcomes — deaths, heart attacks, strokes — rather than biomarker movement alone. A high-profile failure makes it harder to argue that regulators should accept an Lp(a) reduction as a surrogate for benefit, which removes the fastest theoretical route to market for anyone still in the race.

What to watch from here

The near-term items are the full data. A topline miss says a trial did not hit its primary endpoint; it does not say by how much, in which subgroups, or whether there was any signal at all in the patients with the highest baseline levels. Detailed results, when presented, will decide whether the field treats this as a fatal blow to the Lp(a) thesis or as a survivable setback with a narrower path forward.

The second thing to watch is capital allocation at Novartis. A large pharmaceutical company that loses a late-stage cardiovascular asset has a hole in its future revenue profile and a well-established playbook for filling it: business development, licensing, or acquisition. Companies with assets in adjacent cardiometabolic areas tend to see their own share prices firm up in the weeks after a peer's pipeline failure, on exactly that logic.

The third is whether the sector damage sticks. Broad selloffs driven by a single readout often reverse partially within days as investors separate the companies genuinely exposed to the failed hypothesis from those merely sitting in the same index. For long-term holders of the affected names, the useful exercise is working out which category each one is in — and how much of the pre-selloff price actually depended on Lp(a) working.

All prices cited are as of 15:20 GMT on Tuesday, September 8, 2026, with markets open and trading live.

Key facts

• Novartis (NVS): 138.94, down 13.16% as of 15:20 GMT, Sept 8, 2026
• Previous close: 159.99; intraday range 138.28–140.46
• Trial target: Lp(a), a genetically determined cholesterol-carrying blood particle
• Index backdrop: SPY $768.12 (-0.27%), DIA $528.95 (-0.96%), QQQ $720.33 (+0.19%)

Frequently asked questions

What is Lp(a) and why do drugmakers target it?

Lp(a), or lipoprotein(a), is a cholesterol-carrying particle in the blood whose level is set largely by genetics rather than diet or exercise. Elevated Lp(a) is associated with heart attacks and strokes, and standard statins do little to lower it. That left an untreated, measurable risk factor — an attractive target for several drugmakers, including Novartis.

How far did Novartis stock fall?

Novartis shares traded at 138.94 as of 15:20 GMT on September 8, 2026, down 13.16% from the previous close of 159.99. The intraday range was 138.28 to 140.46, meaning the stock spent the session near its lows rather than recovering ground after the initial drop on the failed trial news.

Why did other biopharma stocks fall too?

Because the failure calls the underlying hypothesis into question, not just one molecule. Several drugmakers have bet that lowering Lp(a) reduces cardiovascular events. If that link does not hold clinically, every program aimed at the same target inherits the doubt, which is why the selling spread across the sector rather than staying contained.

Did the broader market fall as well?

Only modestly, and unevenly. The S&P 500 tracker was at $768.12, down 0.27%, and the Dow tracker at $528.95, down 0.96%. The Nasdaq 100 tracker was higher at $720.33, up 0.19%. That split points to damage concentrated in blue-chip healthcare and industrial names rather than a market-wide risk-off move.

What is the difference between a biomarker effect and a clinical outcome?

A biomarker effect means the drug moves a measurement — in this case, the amount of Lp(a) in the blood. A clinical outcome means patients actually have fewer heart attacks, strokes or deaths. Drugs can achieve the first without delivering the second, which is why cardiovascular outcomes trials are large, long and expensive.

What should investors watch next?

Three things: the full trial data, including any subgroup signals in patients with the highest baseline Lp(a); how Novartis reallocates capital after losing a late-stage asset, which often means licensing or acquisition activity; and whether rival Lp(a) programs can credibly argue their trial designs differ enough to produce a different result.

Sources

• Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff — MarketWatch Top

Photo: https://kaboompics.com/ · Pexels Licence — source